# META Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/meta-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Shenzhen, China
- Website: www.metabiopharma.com
- Latest round: Series A (Feb 17, 2025)
- Investors on record: 5

## About

Founded in 2021, and based in Shenzhen, China, META Pharmaceuticals Inc. is a biotech company that focuses on the development of small molecule innovative drugs based on immunometabolism targets. Ke Xu, the company's co-founder and CEO, worked as a consultant at PreScouter Inc. and provided consulting services to well-known biotech companies Taconic and Tesaro. The company's founding team came from two U.S. research hospitals, Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center. In February 2025, the firm raised series A funding led by returning investor XtalPi Inc.. Other returning investor IMO Ventures and new investor Yael Capital also participated in the round.

The company's main products include Meta-01 inhibitors, Meta-02 inhibitors and Meta-03 inhibitors, etc. Meta-01 inhibitors are used in multiple sclerosis, systemic lupus erythematosus, allergic asthma, rheumatoid arthritis, ulcerative colitis and other diseases. Meta-02 inhibitors and Meta-03 inhibitors are used in autoimmune diseases.

The company’s revenue is generated by providing drugs for autoimmune and metabolic diseases.

The company will use the series A funding to accelerate the advancement of two pipeline drugs into clinical trials and further expand the development of its AI metabolic enzyme target discovery platform.

## Funding rounds

- Series A, Feb 17, 2025 — XtalPi Inc., IMO Ventures, Yael Capital
- Seed, Jun 13, 2022 — Tiantu Capital, XtalPi Inc., IMO Ventures, Forcefield Ventures

## Investors

- Tiantu Capital (https://capitalatlas.ai/funds/tiantu-capital) — Seed
- XtalPi Inc. — Seed, Series A
- IMO Ventures (https://capitalatlas.ai/funds/imo-ventures) — Seed, Series A
- Forcefield Ventures — Seed
- Yael Capital (https://capitalatlas.ai/funds/yael-capital) — Series A